Results 251 to 260 of about 101,617 (297)
Some of the next articles are maybe not open access.
Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety, 2021Abstract:: Dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins belong to the class of incretin mimetics. These drugs have been available on the market for the management of type 2 diabetes mellitus (T2DM) for over a decade. Sitagliptin, linagliptin, vildagliptin, saxagliptin and alogliptin are widely available globally, whilst anagliptin ...
Nikhila A. Subrahmanyan +3 more
openaire +2 more sources
DPP-4 inhibitors: focus on safety
Expert Opinion on Drug Safety, 2014Dipeptidyl peptidase inhibitors (DPP-4-i) are highly selective inhibitors of the enzyme DPP-4. They act by increasing levels of incretin hormones, which have potent effects on insulin and glucagon release, gastric emptying, and satiety. Our goal is to review the safety issues related to DPP-4-i.This review is based upon a PubMed search of the ...
Sri Harsha, Tella, Marc S, Rendell
openaire +2 more sources
DPP-4 inhibitors and atherosclerosis: The promise
Atherosclerosis, 20130021-9150/$ e see front matter 2013 Elsevier Irela http://dx.doi.org/10.1016/j.atherosclerosis.2012.12.033 The major cause of mortality and morbidity in diabetes is cardiovascular disease (CVD). Novel therapies that have now been introduced for the treatment of diabetes includingmodulation of the Incretin axis with either glucagon like peptide-1 ...
Ishwarlal, Jialal, Mandeep, Bajaj
openaire +2 more sources
Exploration of the DPP-4 inhibitors with a focus on saxagliptin
Expert Opinion on Pharmacotherapy, 2009Type 2 diabetes (T2DM) has become a worldwide epidemic. Despite a vast array of new compounds to treat T2DM, recommended treatment goals are consistently not achieved in this country thus suggesting a need to increase treatment options.To review the role of DPP-4 inhibitors in treatment of T2DM with an emphasis on saxagliptin.The authors discuss the ...
Jay H, Shubrook +2 more
openaire +2 more sources
Novel DPP-4 Inhibitors Against Diabetes
Future Medicinal Chemistry, 2014DPP-4 specifically degrades the incretin hormone GLP-1 and GIP, both of which are vital modulators of blood glucose homeostasis. Attributed to its potential biological function, DPP-4 inhibition has presently represented an attractive therapeutic strategy for treating diabetes and aroused a significant interest in the pharmaceutical industry.
Yang, Liu, Yongzhou, Hu
openaire +2 more sources
Wildagliptyna – wyjątkowy inhibitor DPP-4
Medycyna Faktów, 2022Wildagliptyna jest jedynym lekiem z grupy inhibitorów DPP-4, który stosuje się 2 razy dziennie. Chociaż nie przeprowadzono badania poświęconego bezpieczeństwu sercowo-naczyniowemu stosowania tego leku, to licznie opublikowane metaanalizy oraz badania obserwacyjne jednoznacznie potwierdziły bezpieczeństwo wildagliptyny w tym zakresie.
openaire +2 more sources
The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies
Expert Opinion on Drug Safety, 2018Type 2 diabetes (T2D), a multifactorial and chronic disease, requires in an elevated percentage of patients the association of several antidiabetic drugs to achieve optimal glycemic control. Dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter inhibitors (SGLT2i) are new classes of oral antidiabetic drugs developed over the last ...
María Molina-Vega +3 more
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2015
Now seven compounds of DPP-4 inhibitor are available in Japan. They can be used in any stage of type 2 diabetes if the insulin secretion capacity is retained; first-line choice to third-line choice or combination with insulin therapy. There is no apparent difference in effect of each DPP-4 inhibitor on glycemic control; HbA1c levels are decreased by 0 ...
Shin-Ichi, Harashima, Nobuya, Inagaki
openaire +1 more source
Now seven compounds of DPP-4 inhibitor are available in Japan. They can be used in any stage of type 2 diabetes if the insulin secretion capacity is retained; first-line choice to third-line choice or combination with insulin therapy. There is no apparent difference in effect of each DPP-4 inhibitor on glycemic control; HbA1c levels are decreased by 0 ...
Shin-Ichi, Harashima, Nobuya, Inagaki
openaire +1 more source
DPP-4 inhibitors: pharmacological differences and their clinical implications
Expert Opinion on Drug Safety, 2014Recently, incretin-based therapy was introduced for the treatment of type 2 diabetes (T2D). In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) play an increasing role in the management of T2D.An extensive literature search was performed to analyze the pharmacological ...
Ceriello A +3 more
openaire +2 more sources
DPP-4 inhibitors: a patent review (2012 – 2014)
Expert Opinion on Therapeutic Patents, 2014Dipeptidyl peptidase 4 (DPP-4) is a serine protease, which catalyzes the hydrolytic process of the amide bond X-Ala or X-Pro at the N-terminus of peptides. This enzyme is involved in the degradation of two incretin hormones glucagon-like peptide-1 and glucose-dependent-insulinotropic polypeptide, which increase the production and release of insulin ...
COSTANTE, ROBERTO +4 more
openaire +3 more sources